Fulminant Type 1 Diabetes
A nationwide survey in Japan
- Akihisa Imagawa, MD1,
- Toshiaki Hanafusa, MD2,
- Yasuko Uchigata, MD3,
- Azuma Kanatsuka, MD4,
- Eiji Kawasaki, MD5,
- Tetsuro Kobayashi, MD6,
- Akira Shimada, MD7,
- Ikki Shimizu, MD8,
- Tetsuya Toyoda, MD9,
- Taro Maruyama, MD10 and
- Hideichi Makino, MD11
- 1Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, Suita, Japan
- 2First Department of Internal Medicine, Osaka Medical College, Takatsuki, Japan
- 3Diabetes Center, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan
- 4Diabetes Center, Kasori Hospital, Chiba, Japan
- 5Unit of Metabolism/Diabetes and Clinical Nutrition, Nagasaki University School of Medicine, Nagasaki, Japan
- 6Third Department of Internal Medicine, University of Yamanashi School of Medicine, Nakakoma, Japan
- 7Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
- 8Ehime Prefectural Central Hospital, Internal Medicine, Matsuyama, Japan
- 9Department of Virology, Kurume University School of Medicine, Kurume, Japan
- 10Department of Internal Medicine, Saitama Social Insurance Hospital, Urawa, Japan
- 11Department of Laboratory Medicine, Ehime University School of Medicine, Ehime, Japan
- Address correspondence and reprint requests to Toshiaki Hanafusa, MD, PhD, FACP, Professor and Chairman, First Department of Internal Medicine, Osaka Medical College, 2–7 Daigaku-machi, Takatsuki, 569-8686, Japan. E-mail: hanafusa{at}poh.osaka-med.ac.jp
Abstract
OBJECTIVE— To describe the clinical and immunologic characteristics of fulminant type 1 diabetes, a novel subtype of type 1 diabetes, we conducted a nationwide survey.
RESEARCH DESIGN AND METHODS—History and laboratory data, including islet-related autoantibodies, were examined in 222 patients with fulminant and nonfulminant type 1 diabetes in our hospitals in addition to another 118 patients with fulminant type 1 diabetes located outside our hospitals in Japan.
RESULTS—In our hospitals, of the 222 patients studied, 43 (19.4%) were diagnosed with fulminant type 1 diabetes, 137 (61.7%) were classified as having autoimmune type 1 diabetes, and 42 were type 1 diabetic subjects who were not fulminant and did not have anti-islet antibodies. An additional 118 fulminant patients outside our hospitals were enrolled, making a total of 161 fulminant type 1 diabetic subjects (83 male and 78 female subjects; 14 children/adolescents and 147 adults) identified from all over Japan. (In 2000, the average incidence was three cases per month.) Flu-like symptoms and pregnancy were more frequently observed in the fulminant than in the autoimmune group (P < 0.001). In the fulminant patients, 4.8% were positive for anti-GAD antibodies and none were positive for anti–islet antigen 2 antibodies.
CONCLUSIONS—Fulminant type 1 diabetes is a distinct subtype and accounts for ∼20% of the ketosis-onset type 1 diabetes cases in Japan. Flu-like symptoms are characteristic of disease onset. Metabolic derangement is more severe in this subtype than in autoimmune type 1 diabetes.
- ADA, American Diabetes Association
- ALT, alanine aminotransferase
- AST, aspartate aminotransferase
- GADAb, GAD antibody
- IAA, insulin autoantibody
- IA-2, islet antigen 2
- IA-2Ab, IA-2 antibody
- ICA, islet cell antibody
- WHO, World Health Organization
Footnotes
-
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.
-
- Accepted May 5, 2003.
- Received December 12, 2002.
- DIABETES CARE











